Jill Feldman, cofounder and president, EGFR Resisters, shares the importance of being proactive in managing dermatologic toxicities in epidermal growth factor receptor (EGFR)–positive lung cancer.

For EGFR IHC, 62 patients were 3+, 4 were 2+, and 1 was 1+. The H-scores range was 50-290, with the median of 250, and the average of 236. Among pure UC, EGFR H-scores range was 130-290, the median ...

While EGFR tyrosine kinase inhibitors (TKIs) are the primary treatment for EGFR-mutant NSCLC patients, resistance inevitably develops, leading to disease progression. JIN-A02, a novel 4 th generation ...

Still, EGFR mutations are more prevalent in the Asian patient population. The frequency is estimated to be around 40% to 50% in Asian NSCLC patients, compared with 10% to 15% in Caucasians.

The COCOON dermatologic management regimen significantly reduced the quality-of-life impact associated with Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) treatment versus the ...

HERTHENA-Lung02 is a global, multicenter, open-label, phase 3 trial evaluating the efficacy and safety of patritumab deruxtecan (5.6 mg/kg every three weeks) monotherapy versus four cycles of doublet ...

BASKING RIDGE, N.J. & RAHWAY, N.J., May 29, 2025--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known ...

HARMONi is a Phase III clinical trial which is evaluating ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic ...

Ivonescimab in combination with chemotherapy showed a positive trend in OS in the primary analysis without achieving a statistically significant benefit with a hazard ratio of 0.79 (95% CI: 0.62 ...